Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II by Benchoua, Alexandra et al.
Dopamine determines the vulnerability of striatal
neurons to the N-terminal fragment of mutant
huntingtin through the regulation of
mitochondrial complex II
Alexandra Benchoua1,{, Yae ¨l Trioulier1,{, Elsa Diguet1, Carole Malgorn1, Marie-Claude Gaillard2,
Noelle Dufour1, Jean-Marc Elalouf2, Stan Krajewski3, Philippe Hantraye1,
Nicole De ´glon1 and Emmanuel Brouillet1, 
1Unite ´ de Recherche Associe ´e, Commissariat a ` l’Energie Atomique (CEA)—Centre Nationale de la Recherche
Scientiﬁque (CNRS) 2210, Service Hospitalier Fre ´de ´ric Joliot, Service MIRCen, Institut d’Imagerie Biome ´dicale
(I
2BM), Direction des Sciences du Vivant, CEA, 4 place du Ge ´ne ´ral Leclerc, 91401 Orsay Cedex, France,
2Commissariat a ` l’Energie Atomique (CEA), Institut de Biologie et Technologies de Saclay (iBiTecS), Service de
Biologie Inte ´grative et Ge ´ne ´tique Mole ´culaire (SBIGeM), Commissariat a ` l’Energie Atomique (CEA) Saclay, 91191
Gif- sur-Yvette Cedex, France and
3The Burnham Institute for Medical Research, 10901 N. Torrey Pines Road,
La Jolla, CA 92037, USA
Received October 11, 2007; Revised and Accepted January 31, 2008
In neurodegenerative disorders associated with primary or secondary mitochondrial defects such as
Huntington’s disease (HD), cells of the striatum are particularly vulnerable to cell death, although the mechan-
isms by which this cell death is induced are unclear. Dopamine, found in high concentrations in the striatum,
may play a role in striatal cell death. We show that in primary striatal cultures, dopamine increases the toxicity
of an N-terminal fragment of mutated huntingtin (Htt-171-82Q). Mitochondrial complex II protein (mCII) levels
are reduced in HD striatum, indicating that this protein may be important for dopamine-mediated striatal cell
death. We found that dopamine enhances the toxicity of the selective mCII inhibitor, 3-nitropropionic acid.
We also demonstrated that dopamine doses that are insufﬁcient to produce cell loss regulate mCII expression
at the mRNA, protein and catalytic activity level. We also show that dopamine-induced down-regulation of mCII
levels can be blocked by several dopamine D2 receptor antagonists. Sustained overexpression of mCII sub-
units using lentiviral vectors abrogated the effects of dopamine, both by high dopamine concentrations
alone and neuronal death induced by low dopamine concentrations together with Htt-171-82Q. This novel path-
way links dopamine signaling and regulation of mCII activity and could play a key role in oxidative energy
metabolism and explain the vulnerability of the striatum in neurodegenerative diseases.
INTRODUCTION
The striatum is preferentially damaged in a number of acute
and chronic neurological conditions, for reasons that are still
unclear. One hypothesis is that the striatum is inherently
sensitive to impairment of energy metabolism. Indeed,
primary genetic mitochondrial defects, the accidental inges-
tion of mitochondrial toxins, perinatal hypoxia/ischemia and
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ation (1).
Among the chronic neurological disorders that affect the
striatum, one of the best studied is Huntington’s disease
(HD). HD is an inherited progressive neurodegenerative dis-
order associated with abnormal movements (chorea), cognitive
deﬁcits and psychiatric disturbances (2). The most striking
neuropathological change in HD is the preferential loss of
medium spiny GABAergic neurons from the striatum (3). At
a genetic level, the disease is caused by an abnormal expan-
sion of a CAG repeat located in exon 1 of the gene encoding
huntingtin protein (Htt) (4). This mutation confers a new toxic
function on the protein, at least in part through the production
of short N-terminal fragments carrying the poly-glutamine
tract. A causal role for these fragments is strongly suggested
by the ﬁnding that mutagenesis of cleavage sites in full-length
mutant Htt inhibits disease progression in mice (5). There is
also compelling evidence that the Huntington phenotype
involves a loss of Htt function (6). Indeed, wild-type Htt has
a pro-survival function, at least in part through the direct regu-
lation of cell death pathways (7–9), and indirectly through the
regulation of the expression (10) and secretion (11) of brain-
derived neurotrophic factor (BDNF).
The expression of wild-type and mutant Htt is virtually ubi-
quitous in the brain, so the mechanisms underlying the prefer-
ential vulnerability of the striatum in HD remain unknown.
One hypothesis is that the toxic effects of mutant Htt are
aggravated by environmental factors that are speciﬁc to the
striatum (12). Among these potential factors, dopamine
(DA), which is found at high concentrations in the striatum,
may render striatal neurons highly sensitive to mutant Htt
(13). Elevation of extracellular dopamine concentration can
be neurotoxic to striatal neurons both in vitro (14,15) and in
vivo (16,17). DA also renders striatal cells highly vulnerable
to degeneration induced by an inhibitor of mitochondrial
complex II (mCII), 3-nitropropionic acid (3NP) (15,18,19).
Direct support for a ‘protoxic’ role for DA in the toxicity of
mutated Htt comes from the recent demonstration that the
toxicity of the N-terminal fragments of mutated Htt is poten-
tiated by DA in striatal neurons in primary culture, an effect
at least partly due to D2 receptor-mediated mechanisms
(20). In addition, in vivo experiments using DAT (dopamine
transporter) knock-out (KO) mice crossed with a knock-in
transgenic mouse model of HD showed that the resulting elev-
ated DA concentration enhances motor symptoms and striatal
degeneration induced by mutant Htt (21). Tang et al. also
recently demonstrated that striatal dysfunction in yeast artiﬁ-
cial chromosome (YAC 128) HD transgenic mice was exacer-
bated by the elevation of DA signaling using L-DOPA
treatment (22). However, the mechanisms by which DA
enhances mutated Htt toxicity have not been elucidated.
One important aspect of HD pathogenesis is mitochondrial
dysfunction. A reduction in mitochondrial membrane potential
is present in various genetic models of HD, as well as in lym-
phoblasts isolated from HD patients (23–25). The activity of
mitochondrial complex II (mCII), an enzyme that plays a
major role in oxidative energy metabolism, is reduced in the
striatum of HD patients (26,27). Additionally, we recently
showed that the loss of mCII activity in the striatum of HD
patients is due to the reduced expression of mCII subunits (28).
A similar loss of mCII subunits and activity was found in stria-
tal neurons in primary culture, following transduction with
lentiviral vectors encoding the N-terminal fragment of
mutated Htt carrying the polyglutamine tract (28).
In the present study, we explored the possibility that mCII
regulation constitutes the missing link that explains the
synergy between the effects of DA and mutant Htt toxicity.
We showed that degeneration of striatal neurons induced by
either the mitochondrial toxin 3NP or lentiviral vectors encod-
ing the ﬁrst 171 amino acids of mutated Htt with 82 polyglu-
tamine repeats (lenti-Htt171-82Q) was dramatically
augmented by the presence of sub-toxic concentrations of
DA. We therefore asked whether DA could down-regulate
mCII expression, and thus increase the vulnerability of striatal
cells to the short fragment of mutant Htt. To this purpose, we
characterized the cellular and biochemical changes that occur
during neurodegeneration produced by dopamine and mutated
Htt fragment, and performed rescue experiments using lenti-
viral vectors encoding mCII subunits. The results show that
dopamine increases the vulnerability of striatal neurons to
mutant Htt toxicity via a down-regulation of mCII expression
that involves an upstream activation of D2 pharmacological
subtype of dopamine receptors.
RESULTS
Dopamine enhances the toxicity of the N-terminal
fragment of mutated huntingtin
DA (100 mM) was shown previously to increase the toxicity of
the N-terminal fragment of mutated huntingtin (exon 1 of Htt
with 123 polyglutamine repeats), expressed acutely after trans-
fection (20). In the present study, we examined whether DA
similarly affected the progressive toxicity at low levels of a
shorter N-terminal fragment of mutated Htt (171 ﬁrst amino
acids with 82 glutamines) expressed using lentiviral vectors
in a model where neuronal cell loss is only detected at 6–8
weeks post-infection (28,29).
The dose-dependent neurotoxic effects of DA were
re-examined under our experimental conditions using
two cell death/viability assays: reduction of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), an index of the integrity of dehydrogenases and detec-
tion of lactate dehydrogenase (LDH) that is released from the
cytosol to the extracellular space during cell death. Both
assays indicated an absence of major degeneration of striatal
cell at or below 100 mM DA (Fig. 1A), while signiﬁcant
degeneration was seen at DA concentrations  250 mM.
Thus, to study the ‘protoxic’ effect of DA, we treated striatal
neurons with 100 mM DA for 24 h, after initial co-transduction
with lentiviral vectors encoding GFP and either Htt171-82Q or
Htt171-19Q (19 polyglutamine repeats; control). The simul-
taneous exposure of neurons to both vectors resulted in the
co-expression of the two transgenes (GFP and one form of
Htt) by nearly all cells (97%; 29, Supplementary Material,
Fig. S1), which allowed direct counts of neurons that survived
DA treatment (Fig. 1B). In agreement with our previous work
(28), Htt171-82Q alone induced low levels of cell death at 6
weeks post-infection. DA treatment did not result in the
degeneration of cells expressing Htt171-19Q, whereas in
Human Molecular Genetics, 2008, Vol. 17, No. 10 1447cultures expressing Htt171-82Q, DA induced a 3-fold drop in
the number of surviving GFP-positive cells. We also studied
cell death after a 24 h treatment with 100 mM DA, using the
LDH assay (Fig. 1C). The addition of DA augmented neuronal
degeneration in cultures expressing Htt171-82Q, but did not
affect striatal cells expressing Htt171-19Q or non-infected
cells, conﬁrming that DA treatment increased the toxicity of
Htt171-82Q under our experimental conditions.
The sensitization of striatal cells by dopamine is associated
with mCII down-regulation
We next wanted to determine whether mCII depletion is impli-
cated in the DA-induced increase of Htt171-82Q-mediated
toxicity. We therefore explored whether striatal cells with
mCII deﬁcits induced by 3NP were more vulnerable to DA
than untreated cells, as was previously suggested by in vitro
(15) and in vivo (18) experiments. A combination of 100 mM
DA and a non-toxic concentration of 3NP (30) induced the
degeneration of striatal cells (Fig. 2), while either DA or
3NP alone had no effect. This suggests that under our cell
culture conditions, minimal/sub-acute mCII deﬁcits rendered
striatal neurons highly vulnerable to DA treatment.
We next examined whether DA could regulate mCII subunit
levels. Western blot analysis was used to evaluate the protein
levels of the two largest mCII subunits, namely Fp (ﬂavopro-
tein, SDH-A, 70 kDa) and Ip (Iron-sulfur protein, SDH-B;
30 kDa); each are components of succinate dehydrogenase
(SDH). Both Fp and Ip levels were signiﬁcantly reduced
after a 24 h DA treatment, in a concentration-dependent
manner (Fig. 3A and B). Biochemical analysis of succinate
oxidation, a direct index of SDH/mCII catalytic activity,
also demonstrated a dose-dependent reduction in the enzy-
matic function of the complex (Fig. 3C). In order to determine
the selectivity of these alterations, we analyzed the expression
of other mitochondrial proteins. Our results show that, in con-
trast to mCII subunits, the levels of the four other proteins
tested (BclXL, subunit 4 of complex IV, alpha subunit of
complex V and the 39 kDa subunit of complex I) remained
unchanged (Fig. 3D). This indicates that the changes in
mCII subunit expression were not due to a global reduction
of mitochondrial proteins.
We studied whether the dopamine-induced alterations of
mCII expression could result from loss of expression in
Figure 1. Synergistic effects of mutated huntingtin and dopamine on striatal
neuron degeneration. (A) Dose-dependent toxicity of DA (24 h treatment)
assessed in striatal neurons (21 DIV) using the LDH and MTT cell death/via-
bility assays. Note the clear-cut toxicity of DA above 250 mM.( B) Effect of
100 mM DA on the survival of striatal neurons 4 weeks after simultaneous
transduction with a lentiviral vector encoding Htt171-82Q (mutated) or
Htt171-19Q (wild-type), and a lentiviral vector encoding the reporter GFP.
Neither DA alone nor Htt171-82Q alone is toxic to GFP-labeled neurons at
this time point, but a combination of the two results in a 3-fold reduction in
the number of neurons compared with Htt171-82Q controls. (C) Cell death
assessed using the LDH assay in an experiment similar to that in (B), in the
absence of lentiviral GFP. In the presence of DA, LDH release is signiﬁcantly
increased in cultures expressing Htt171-82Q. No LDH activity was observed
without DA (data not shown).  P , 0.05; ANOVA and Fisher’s post-hoc
PLSD test.
Figure 2. Synergistic effects of mitochondrial complex II deﬁcits and dopa-
mine on striatal neuron degeneration. Cell viability assessed by the MTT
assay after treatment for 24 h with 3-NP (75 mM), an irreversible inhibitor of
mCII, and DA (100 mM). Note that when applied alone, 3-NP is non-toxic
and DA is very mildly toxic. Treatment with both agents synergistically
induces cell death.  P , 0.0001; ANOVA and Fisher’s post-hoc PLSD test.
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cultures at 4 weeks in vitro. Qualitative immunoﬂuorescence
and quantitative FACS analyses conﬁrmed that striatal cul-
tures consisted of a relatively low proportion of astrocytes
(12%) whereas cells with a neuronal phenotype (80%)
predominated (Supplementary Material, Fig. S2). We also
examined the potential effect of dopamine on astrocytes. We
treated pure astrocyte cultures with increasing concentrations
(100–300 mM) of dopamine and found no effect of the neuro-
transmitter on SDH/mCII expression in these glial cells (Sup-
plementary Material, Fig. S3). These results suggested that the
dopamine-induced loss of mCII subunits in striatal cultures
most likely corresponded to an alteration of expression in
neurons.
The effect of DA on transcription of Fp and Ip genes was
explored in primary culture of striatal neurons. Levels of
SDH-A (Fp) and SDH-B (Ip) gene transcripts were evaluated
by quantitative RT–PCR at different times after DA treat-
ment. Levels of both SDH-A and SDH-B transcripts were
signiﬁcantly decreased 16 h after DA treatment (Fig. 3E).
At 24 h, SDH-A mRNA levels returned to original values,
whereas the expression of SDH-B transcripts remained
down-regulated. At 48 h after DA treatment, the levels of
both SDH-A and SDH-B transcripts were similar to those
of control cells. The depletion of mCII catalytic subunits
and activity seen at 24 h could thus result, at least in part,
from the reduction in the transcription of SDH genes 8 h
earlier.
Figure 3. Cumulative effects of dopamine and mutated huntingtin on mCII expression and catalytic activity. Measurement of Ip and Fp protein expression levels
as indicated by western blotting, and mCII activity in striatal cultures treated for 24 h with increasing concentrations of DA. (A) Representative western blot
showing the reduction of Ip and Fp expression, while levels of the alpha-subunit of complex V (C-V) remain essentially unchanged. (B) Quantiﬁcation of
protein levels for Ip and Fp after western blotting. (C) Dose-dependent effect of a 24 h DA treatment on the catalytic activity (succinate dehydrogenase) of
mCII. (D) Quantiﬁcation of protein levels for BclXL, the alpha-subunit of complex V (C-V), subunit 4 of complex IV (C-IV) and the 39 kDa subunit of
complex I (C-I) after 100 mM DA treatment. (E) Changes in Ip and Fp mRNA levels over time during a 100 mM DA treatment, using quantitative RT–
PCR. Note the transient down-regulation of both transcripts. (F) mCII activity in striatal neurons transduced with lentiviral Htt171-82Q (mutant) or
Htt171-19Q (wild-type), before treatment with 100 mM DA or vehicle. The effects of DA and mutated Htt on the reduction of mCII activity are cumulative,
and correspond to the synergistic effects on neuronal degeneration seen in Figure 1.  P , 0.05;   P , 0.001;
#P , 0.01; ANOVA and Fisher’s post-hoc
PLSD test.
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striatal neurons to mutated Htt after treatment with DA
could be related to a cumulative depletion in mCII levels.
We measured the enzymatic activity of mCII after a 24 h treat-
ment with DA in uninfected cells, and neurons transduced
with either Htt171-19Q or Htt171-82Q. Our results showed
that the expression of Htt171-82Q induced a signiﬁcant
(20%) reduction in mCII activity when compared with
Htt-171-19Q transduced controls (Fig. 3F), in agreement
with previous ﬁndings (28). Interestingly, treatment with
100 mM DA also induced a reduction (23%) in complex II
activity in neurons transduced with lenti-Htt171-19Q. DA
treatment of cells expressing Htt171-82Q resulted in a cumu-
lative reduction (40%) of mCII activity (Fig. 3F), suggesting
that SDH/mCII depletion could be a critical event underlying
the ‘sensitization’ of striatal cells in the combination of
Htt171-82Q and DA.
Overexpression of mCII subunits rescues striatal cells
from DA and mutated Htt toxicity
We asked whether the loss of mCII could be instrumental to
the toxicity of DA in normal cells and to the ‘protoxic’
effect in striatal cells expressing the mutated Htt fragment.
To this end, lentiviral vectors expressing SDH-A (lenti-Fp)
and SDH-B (lenti-Ip) were used (28).
We used western blots to examine whether the overexpres-
sion of mCII subunits could block the effects of DA in normal
cells. A profound loss of mCII was seen in DA-treated cells,
whereas transduction with lenti-Ip and lenti-Fp reversed this
loss (Fig. 4A). We then assessed whether the maintenance of
mCII levels correlated with a neuroprotective effect. LDH
assays and FACS analysis of TUNEL-positive cells revealed
that the toxicity of DA was markedly reduced by the over-
expression of Ip and Fp mCII subunits (Fig. 4B and C). Quan-
titation of GFP-positive cells further conﬁrmed that lenti-Ip
rescued neurons from DA toxicity (Fig. 5). The loss of mCII
thus appears to play a causal role in DA-induced toxicity in
striatal neurons that do not express mutated Htt.
To test whether mCII loss is similarly involved in the
exacerbation of DA toxicity in striatal neurons expressing
mutated Htt, the cells were transduced with lentiviral vectors
encoding Htt171-82Q or Htt171-19Q as described earlier,
and re-infected with either lenti-Fp or lenti-Ip 1 week later.
After 5 weeks, the cells were treated with 100 mM DA. Ip
and Fp overexpression signiﬁcantly protected neurons
against death induced by the combination of DA and
Htt171-82Q (Fig. 6). Thus, mCII loss is, at least in part,
involved in the toxicity of DA in cells expressing the
mutated Htt fragment.
The dopamine-induced down-regulation of mCII
expression depends on the activation of D2 receptors
In order to further investigate the mechanisms underlying the
DA-mediated depletion of mCII subunits, we focused on the
interaction of DA with its membrane receptors, D2 and D1.
We measured the activity of mCII in neurons treated with
100 mM DA in the presence or absence of D1 and D2 receptor
antagonists. Spiperone and haloperidol, two D2-receptor
antagonists, totally abolished the effects of DA on mCII
activity (Fig. 7A). In contrast, the D1-receptor antagonist
SCH 23390 did not alter the DA-induced reduction of mCII/
SDH activity. Similar experiments were performed to assess
mCII subunit expression levels. Western blot analysis demon-
strates that the loss of mCII Ip and Fp induced by DA was
blocked by the D2 receptor antagonists (Fig. 7B). In contrast,
Figure 4. Rescue of striatal neurons from DA toxicity by lentiviral mCII com-
ponents, Fp and Ip. Effects of DA on mCII Ip and Fp subunit expression in
neurons plated for 3 weeks in culture. Cultures were exposed to 300 mM DA
for 24 h, 2 weeks after transduction with lentiviral vectors coding Ip
(lenti-Ip) or Fp (lenti-Fp) proteins or vehicle alone. (A) Levels of Ip and Fp
assessed by western blot analysis reveal that the overexpression of mCII sub-
units compensates for the loss induced by DA. (B and C) Evaluation of the
protective effects of Ip and Fp overexpression using the LDH assay (B) and
counts of TUNEL-positive cells by FACS (C). Note that the overexpression
of Ip and Fp mCII subunits is neuroprotective.  P , 0.0001; ANOVA and
Fisher’s post-hoc PLSD test.
1450 Human Molecular Genetics, 2008, Vol. 17, No. 10the D1 receptor antagonist was ineffective. Another selective
antagonist of D2 receptors, raclopride, also blocked the
effect of DA on mCII subunit expression, whereas the direct
activation of D2 receptors by the DA agonist quinpirole sig-
niﬁcantly reduced mCII expression in striatal cells, replicating
the effect of DA (Fig. 8).
These data suggest that DA regulates the expression of
mCII activity by decreasing Ip and Fp subunit expression,
an effect at least partly mediated by D2 receptor activation.
DISCUSSION
The present study shows that the treatment of primary cultures
of striatal neurons with DA induces neurodegeneration that is
accompaniedbythedecreasedlevelsofanimportantmitochon-
drialenzyme,mCII.Thisisinagreementwithpreviousﬁndings,
including studies of primary neuronal cultures, in which DA
was consistently found to be cytotoxic at the concentration
range used in our study (reviewed in 15). These in vitro
results are highly relevant to the vulnerability of striatal cells
in vivo. Indeed, an acute elevation of DA levels in the striatum
by intrastriatal stereotaxic injections induces neuronal degener-
ation (17). A sustained increase in extracellular concentrations
of DA in DAT KO mice also leads progressively to striatal
cell loss (16). However, the mechanisms involved in DA tox-
icity have not yet been fully elucidated (13).
Figure 5. Microscopic analysis of the effects of Ip mCII subunit overexpres-
sion on DA-induced neuronal death. Cultures of striatal neurons expressing the
reporter gene GFP, were transduced with a lentiviral vector coding the Ip
subunit of mCII (lenti-Ip) or the DsRed reporter protein (lenti-DsR) as a
control of transduction. (A) Representative ﬁeld of view using phase contrast
imaging (upper images) and ﬂuorescence imaging of GFP (lower images)
(Scale bar, 20 mm). (B) Histogram of GFP-positive cell counts in cultures
transduced with lenti-Ds or lenti-Ip after a 24 h treatment with DA. Note
the severity of neurodegeneration in cultures treated with DA, and the rescuing
effect of Ip overexpression.  P , 0.005; ANOVA and Fisher’s post-hoc PLSD
test.
Figure 6. Rescue of striatal neurons by Ip and Fp overexpression from the
synergistic degeneration induced by DA and mutated Htt. Striatal cell cultures
transduced with either Ip or Fp subunits of mCII in addition to Htt171-82Q are
less vulnerable than mock-infected controls to neurodegeneration induced by
100 mM DA treatment 6 weeks later (i.e. before the bulk of cell death produced
by Htt171-82Q alone). Note that neurons expressing Htt171-82Q are more vul-
nerable to DA than those expressing Htt171-19Q.  P , 0.05 and   P ,
0.0001 (Htt171-82Q versus htt171-19Q);
#P , 0.005 (Fp or Ip transduction
versus mock-infection, in htt171-82Q expressing cells). ANOVA and
Fisher’s post-hoc PLSD test.
Figure 7. D2 receptor inhibition reduces the DA-induced loss of mCII subunit
expression and activity. Neurons were treated with 100 mM DA for 24 h in the
presence or absence of the D2 receptor antagonists spiperone (SPI) and halo-
peridol (HAL), and the D1 receptor antagonist SCH23390 (SCH). (A) Quanti-
ﬁcation of the catalytic activity of mCII (succinate dehydrogenase). (B)
Western blot analysis of Fp and Ip corresponding to the culture wells analyzed
for mCII activity above. In both cases, the blockade of D2 receptors abolishes
the loss of mCII triggered by DA, while D1 receptor blockade has no effect.
 P , 0.05; ANOVA and Fisher’s post-hoc PLSD test.
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rodegeneration through the reduction of mCII expression. In
support of this hypothesis, we found that DA reduces mCII
catalytic activity. This effect is associated with a reduction
in the expression of the Ip and Fp subunits of mCII, as indi-
cated by western blotting and quantitative RT–PCR assays.
Importantly, when the expression of these subunits is artiﬁ-
cially increased using lentiviral vectors, DA appears to be sig-
niﬁcantly less toxic, indicating that the loss of mCII is
instrumental in DA-induced neurodegeneration. Since the len-
tiviral vectors we use in the present study preferentially trans-
duce neurons (28,29,31), these results suggest that the
phenomena we observe mainly involve neurons and not astro-
cytes. In line with this, our striatal cultures mostly contain
neurons with a low proportion of astrocytes. In addition, we
showed that mCII expression in astrocytes is insensitive to
dopamine treatment, even at concentrations shown to kill
neurons.
Interestingly, we demonstrated that mCII depletion after DA
treatment is linked to D2 activation, as D2 (but not D1) antag-
onists block the DA-induced reduction in mCII subunit
expression. Further supporting the potential role of D2 recep-
tors, the agonist quinpirole mimics the effects of DA on mCII
expression. To our knowledge, this is the ﬁrst evidence that
DA might directly regulate mitochondrial physiology
through a speciﬁc signaling pathway involving DA membrane
receptors.
The underlying mechanisms linking D2 receptor activation
and the down-regulation of mCII remain to be elucidated. A
careful analysis of the effects of DA on neuronal survival indi-
cates that the reduction in mCII levels occurs in the absence of
detectable cell loss, and is highly selective. In addition, the
mRNA levels of mCII subunits are depleted transiently.
These observations rule out any possibility that the loss of
mCII is proportional to the extent of cell death, and indicate
the existence of a relatively speciﬁc mechanism that controls
mCII levels. DA signaling through the D2 receptor subfamily
is complex and involves multiple factors, including heterotri-
meric G proteins, adenylyl cyclase, cAMP, PKA and intra-
cellular Ca
2þ (reviewed in 32). Other signaling pathways
have recently been unraveled. Of particular interest is the
ﬁnding that D2-like receptors signal by down-regulating Akt
via a beta-arrestin-2 and protein phosphate 2A interaction
(33). The activation of ERK has also been reported after D2
receptor stimulation (34). Ongoing experiments in our lab
aim to discover which of the pathways activated by D2-like
receptors might regulate mCII.
Our study identiﬁes a novel pathway linking DA signaling
to mitochondrial function. There is a growing body of evi-
dence indicating that mitochondria can be ‘linked’ to the
external environment through a variety of mechanisms/path-
ways. Mitochondria receive a variety of signals inﬂuencing
the death/survival balance, and play a central role in apoptosis
(35). The integration of signals at the mitochondrial level
could also participate in other physiological processes not
directly associated with cell death. For example, during neur-
onal activation at the glutamatergic synapse, post-synaptic
mitochondria are sensors of synaptic activity through their
capacity to rapidly uptake the Ca
2þ that enters via activated
cation channels (36). Ca
2þ changes within the mitochondria
have important functional consequences, including the modu-
lation of respiratory chain activity. In line with this, a new type
of mechanism linking an extracellular signal to mitochondrial
regulation through the intervention of transmembrane proteins,
the integrins, has been described (37). Similarly, the link
between D2 receptor signaling and mCII might constitute an
original mechanism allowing post-synaptic regulation in
response to a sustained elevation of dopamine concentrations.
The physiology of this pathway remains to be deﬁned, but
might represent an integrated response for controlling energy
demand. Consistent with this speculation, the stimulation of
D2 receptors is generally considered to inhibit striatal
medium spiny neuron ﬁring. Thus, a D2-induced reduction
in energy consumption associated with reduced ﬁring might
be coordinated on a long-term basis with a reduction of
energy production through the regulation of mCII expression.
The present results indicate that the effect of DA on mCII
expression may play a role in pathological conditions associ-
ated with striatal degeneration, especially in HD. The striatum
is a brain region that plays an important role in the control of
movement and cognitive function. For unknown reasons, the
striatum is damaged in several neurodegenerative disorders
associated with a chronic impairment of energy metabolism
(1). Intoxication with mitochondrial toxins often induces stria-
tal necrosis. This exquisite sensitivity of the striatum to
impairments in energy metabolism remains a mystery, but
convergent lines of evidence indicate that the nigro-striatal
Figure 8. Activation of D2 receptors down-regulates the level of mCII subunits.
Striatal cultures were treated for 24 h with either the D2 agonist quinpirole
(QUIN) or with 100mM DA in the presence or absence of the D2 antagonist
raclopride (RACLO). (A) Representative western blot showing the levels of
Ip and Fp under the various experimental conditions (all images are from the
same blot). (B) Quantiﬁcation of western blots for Ip and Fp. Note that quin-
pirole mimics the effect of DA on Ip and Fp expression, while raclopride has
a restorative effect similar to that of spiperone and haloperidol (see Fig. 7).
 P , 0.05;   P , 0.01 (Untreated and racloprideþDA groups compared with
quinpirole and DA only groups). ANOVA and Fisher’s post-hoc PLSD test.
1452 Human Molecular Genetics, 2008, Vol. 17, No. 10dopaminergic pathway may play a ‘permissive’ or ‘facilitat-
ing’ role (reviewed in 12). Our present results further substanti-
ate this hypothesis and demonstrate that DA, via an interaction
with D2 receptors, directly regulates the levels of mCII in
striatal neurons. mCII has an important role at the intersection
of the TCA cycle and the respiratory chain, since the reduction
of succinate to fumarate results in electron feeding to ubiqui-
none and complex III (ubiquinone–cytochrome c oxido-
reductase). Thus mCII plays a key role in oxidative energy
metabolism. In pathological situations where DA metabolism
or levels are increased, as during hypoxia, ischemia and intoxi-
cation with mitochondrial poisons, the down-regulation of
mCII would further increase the vulnerability of striatal cells
to cell death.
We observed that DA in association with mutated Htt
expression cumulatively reduces mCII expression. Under our
experimental conditions, this enhanced reduction synergisti-
cally triggers neurodegeneration, whereas neither DA nor
mutated Htt alone were toxic. We also demonstrate that the
overexpression of mCII using lentiviral vector-mediated
gene transfer protects striatal neurons against the toxicity
induced by the combination of mutated Htt and DA. This
further supports the hypothesis that mCII deﬁcits play a role
in striatal degeneration in HD (28). We previously showed
that mCII/SDH expression is preferentially lowered both in
the striatum of HD patients and in primary striatal neurons
expressing the N-terminal segment of mutated Htt (171
amino acid with 82 glutamine repeats), while the expression
of other mitochondrial proteins remains essentially unchanged
(28). Interestingly, the reduction in Fp and Ip proteins was not
seen in the cerebral cortex or cerebellum of HD patients,
suggesting that the preferential loss of mCII in the striatum
of HD patients (26–28) might involve, at least in part, a
factor highly enriched in the striatum. The present study
suggests that DA, present at high concentrations in the
striatum, could augment the mCII deﬁcits mediated by
mutated Htt.
No evidence exists for the increased release of DA in HD.
The concentrations of DA and its metabolites in the HD stria-
tum are relatively conserved or even slightly reduced in grade
II/III patients (13,38). PET scan studies with 11C-raclopride
have demonstrated a reduction in the density of D2 antagonist
binding sites at the onset of the disease (39). DA signaling
dysfunctions have also been reported in transgenic mouse
models of HD (40). This apparent ‘slow-down’ of DA signal-
ing in HD does not contradict our hypothesis that DA could
play a role in HD pathogenesis. First, the effect of DA signal-
ing on mCII regulation might occur at a relatively early stage
of the disease. Another important aspect is that if an apparent
‘slow-down’ of DA signaling does take place, a sustained
down-regulating effect of residual DA on mCII expression
in the HD striatum could be maintained and be larger than
in regions devoid of major DA afferents, such as the cerebral
cortex. Therefore, residual DA signaling might still be able to
enhance the effects of mutant Htt on mCII in the striatum of
HD patients, supporting the idea that the DA signaling
pathway is a therapeutic target for slowing disease pro-
gression. Further supporting this hypothesis, the recent work
of Tang et al. (22) demonstrated that in mice expressing the
full length mutant Htt and treated with L-DOPA to elevate
dopamine concentrations and accelerate striatal degeneration,
the neuroleptic tetrabenazine was neuroprotective. In addition,
we recently reported that chronic treatment with the D2 antag-
onist haloperidol signiﬁcantly reduces the striatal toxicity
Htt171-82Q in vivo (41). In line with this, Stack et al. (42)
showed that 6OHDA-induced degeneration of the
nigro-striatal dopaminergic pathway in R6/2 HD mice
improves the pathology, in particular extends survival.
In conclusion, the present study demonstrates that DA,
through a D2-mediated mechanism, regulates the expression
levels and catalytic activity of mCII. Our results indicate
that through this novel pathway, DA may act synergistically
with mutant Htt to trigger the preferential degeneration of
the striatum in HD.
MATERIALS AND METHODS
Primary embryonic striatal neurons and primary culture
of astrocytes
Primary striatal neurons from E14 to E15 rat embryos were
cultured as previously described (28,29). Timed-pregnant
Sprague-Dawley rats (Janvier, Le Genest-St-Isle, France)
were killed with a lethal dose of pentobarbital, and embryos
were quickly removed and dissected in cooled Hank’s
balanced salt solution (without Ca
2þ and Mg
2þ, Sigma).
Ganglionic eminences were isolated and incubated for
15 min at 378C in 0.3 mg/ml DNAse I (Sigma, St Louis).
The tissue was mechanically dissociated with a ﬁre-polished
Pasteur pipette and the debris removed by decantation of the
suspension. The cells were then concentrated by centrifugation
(208C, 5 min, 1500 g) and resuspended in serum-free Neuro-
basal medium supplemented with 2% B27 supplement
(Gibco Brand, InvitroGen, Carlsbad, CA), 1% antibiotic–
antifungal mixture (Gibco), and 0.5 mM L-Glutamine
(Sigma). The cells were plated at a density of 400 000 cells/
well in 24-well Costarw plates coated with 50 mg/ml 30–
70 kDa Poly-D-lysine (Sigma). The cultures were kept in a
humid incubator (5% CO2,3 7 8C) and half the medium was
changed once per week.
Primary cultures of astrocytes were prepared from striatum
of E19 embryos of Sprague-Dawley rats according to the
method of Vega et al. (43) with modiﬁcation. Striatum were
dissected in cooled Hank’s balanced salt solution (without
Ca
2þ and Mg
2þ, Sigma) and placed in a medium containing
50% Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco),
50% F12 (Gibco), 10% SVF and 1% antibiotic–antifungal
mixture (Gibco). Cells were dissociated through needles of
decreasing gauge sizes (1.1   40 mM, 0.9   25 mM, 0.6  
20 mM). Then cells were plated at 200 000 cell/cm
2. Culture
medium was replaced 4–5 days after seeding and sub-
sequently every 2–3 days. Before changing medium, plates
were gently tapped to remove the less adherent oligodendro-
cytes, oligodendrocyte-type 2 astrocyte progenitor cells and
microglia, but not the astrocytes. Three weeks after plating,
cultures were treated with increasing doses of dopamine
(100–300 mM) for 24 h.
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The cDNA coding for the ﬁrst 171 amino acids of human hun-
tingtin, containing 19 or 82 CAG repeats (htt171-19Q/82Q),
GFP, DsRed, human SDH-A and SDH-B were cloned into
the SIN-W-PGK transfer vector as previously described
(28,29). Viral production was carried out in 293T cells with
a four plasmid system (44). The viruses were re-suspended
in PBS with 1% BSA and matched for particle concentration
after measurement of p24 antigen content. Twenty-four
hours after plating (1 day in vitro; DIV), the cell cultures
described earlier were exposed to the lentiviral vectors, each
at a concentration of 10 ng p24/10
5 cells. At 2 DIV, half of
the medium was replaced with freshly prepared culture
medium. For rescue experiments, Htt-encoding vectors alone
or mixed with GFP encoding vectors (in a 2/1 lenti-Htt/
lenti-GFP ratio) were used as described earlier and a second
transduction was performed 1 week later with one of the
SDH-encoding vectors or with the DsRed-encoding vector
used as a control. Previous quantitative RT–PCR analyses at
3 weeks have shown that the transcriptional levels of
Htt171-82Q and Htt171-19Q are similar when lentiviral
vectors are matched for p24 antigen levels (29). The transduc-
tion efﬁciency, as demonstrated by the increased expression of
SDH-A (Fp subunit) and SDH-B (Ip subunit), was re-tested by
western blot analysis at 21 DIV, or 2 weeks after treating cells
with the lentiviral vectors (28).
Dopamine treatment, cell death evaluation and
immunoﬂuorescence
DA (Sigma) was freshly prepared as a 100  solution in a
Neurobasal medium and directly added to the culture
medium of 4 week in vitro cultures, at least 5 days after chan-
ging half the medium. Cell death was evaluated by different
approaches. The level of LDH that is released upon cell
death was measured in culture medium samples (20 ml) col-
lected at 24 h, using the LDH colorimetric assay kit (Roche
Pharma, Switzerland) following the manufacturer’s instruc-
tions (30). Cell viability was also assessed after DA treatment
by colorimetric measurement of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma) reduction
as previously described (45). In one experiment, FACS analy-
sis of the number of cells positive for TUNEL (an indicator of
death related to DNA fragmentation) was performed as
described earlier (28,29).
Cells were directly counted after co-transduction with lenti-
viral vectors encoding GFP. For this, we took advantage of
lentiviral vectors that preferentially transduce neurons (29).
GFP-positive cells were counted using an inverted epiﬂuores-
cence microscope (CKX41, Olympus, France) equipped with
an image acquisition and analysis system (Explora Nova, La
Rochelle, France). Five-to-ten ﬁelds of view randomly posi-
tioned throughout the coverslips were acquired. The number
of GFP-positive cells in the ﬁeld of view was automatically
determined by thresholding the image. The average number
of GFP cells per ﬁeld of view was calculated for each cover-
slip. Between 4 and 8 cell-culture wells/coverslips per experi-
mental condition, in triplicate, were used for statistical
analysis.
For determination of the proportion of astrocytes versus
neurons immunoﬂuorescence labeling of cultured cells was
performed on coverslips at 3 and 4 week in culture. After ﬁx-
ation with PFA 4%, and blocking with normal goat serum,
cells were incubated with a monoclonal mouse anti-TUJ-1
(Co ance, 1:500), a mouse monoclonal anti-MAP2 (Chemicon,
1:500) or a mouse monoclonal anti-GFAP (Sigma, 1:200).
Fluorescent secondary antibody was a goat anti-mouse
Alexa-555 (1:1000). For FACS analysis of cell markers, the
secondary antibody was a goat anti-mouse Alexa-488
(1:1000).
Western blot analysis
Cultures were trypsinized and collected by centrifugation
(1000 g, 10 min). The pellets were incubated on ice in lysis
buffer [150 mM NaCl, 50 mM Tris pH 8.0, 5 mM EDTA,
0.5% Triton, 1% NP 40 and 0.5% protease inhibitor cocktail
(Sigma)] for 30 min with vortexing every 10 min. Homogen-
ates were centrifuged at 13 000g for 30 min at 48C and super-
natants were stored at 2808C. Protein concentrations were
determined with the BCA protein assay (Pierce, Rockford,
USA). Protein (10 mg) was resolved on a 12% SDS–PAGE
gel and transferred onto polyvinylidene diﬂuoride membranes.
Membranes were incubated in 5% nonfat dry milk in TBS con-
taining 0.1% Tween 20 (T-TBS) for 2 h at room temperature
with the following primary mouse monoclonal antibodies
(Molecular Probes): anti-70 kDa (SDH-A or Fp) subunit of
complex II, 1/3000; anti-30 kDa (SDH-B or Ip) subunit of
complex II, 1/3000; anti- cytochrome oxidase (complex IV)
subunit IV, 1/500; anti-39 kDa subunit of complex I (1/
1000). The membranes were also probed with a polyclonal
anti-BclXL antibody (1/1000, Burnham Institute). After a
1 h-incubation with anti-mouse or anti-rabbit IgG
HRP-coupled secondary antibodies (1/5000, Amersham Phar-
macia Biotech., Les Ulis, France), the antigens were revealed
using Enhanced Chemiluminescence Reaction (ECL, Amer-
sham Pharmacia Biotech.). Blots were routinely stripped in a
denaturing solution (Tris–HCl 0.5 M pH 6.8, SDS 10%, beta-
mercaptoethanol 0.8%), and reprobed with a monoclonal
anti-alpha-subunit of mitochondrial complex V (F1-ATPase,
Molecular Probes) and an anti-actin (monoclonal/polyclo-
nal—which species) (1/10 000, Sigma). Coomassie blue was
used as an absolute control for total protein loading. Signal
intensity was quantiﬁed using TotaLab software (Amersham)
and normalized to coomassie values (28).
SDH activity assay
SDH activity was measured using Iodonitrotetrazolium chlor-
ide (INT, Sigma) as previously described (46). Typically,
1.5   10
6 cells were homogenized using a glass dounce hom-
ogenizer in a mitochondrial buffer containing 20 mM Tris–
HCl pH 7.2, 250 mM saccharose, 2 mM EGTA, 40 mM KCl
and 1 mg/ml BSA. Homogenates were centrifuged at 1500g
for 5 min at 48C and the supernatant processed immediately
for SDH activity, or stored at 2808C until further use. The
homogenate (20 ml) was diluted in 2  activity buffer
(100 mM Tris–HCL pH 8.3, 1 mM EDTA) containing
20 mM succinate. The reaction was started by adding 2 mM
1454 Human Molecular Genetics, 2008, Vol. 17, No. 10of INT, and samples incubated for 90 min at 378C. The for-
mation of red formazan produced by INT reduction was
measured at 490 nm with a spectrometer (Biorad). OD
values were normalized to the quantity of protein used; back-
ground OD was measured by omitting succinate from the reac-
tion medium. For each experimental condition, background
OD was subtracted from the total OD in the presence of suc-
cinate to obtain INT reduction due speciﬁcally to SDH
activity.
Real-time RT–PCR
Total RNA was extracted from 1.5   10
6 cells using guani-
dium thiocyanate/phenol followed by digestion with RQ1
DNase (Promega, France). The RT reaction was performed
with 200 ng of total RNA using Superscript II reverse tran-
scriptase (Invitrogen) followed by treatment with RNase
H. Real-time quantitative PCR was carried out with 1% of
the RT product, using an ABI 7000 Sequence Detection
System (Applied Biosystems), and PCR products were quanti-
ﬁed by measuring SYBR Green ﬂuorescent dye incorporation.
Values obtained for SDH mRNA were normalized to the cor-
responding value of the reference mRNA for cyclophilin
A. Primers were designed using Oligo 6.3 software and are
available from the authors upon request.
Statistical analysis
Data are expressed as mean+SEM. One way ANOVA was
performed to compare differences between groups, followed
by a Fisher’s post-hoc PLSD test. A P-value ,0.05 was con-
sidered signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
We thank Nathalie Lefort for her help with the FACS analyses
and Dr Jocelyne Caboche and Delphine Charvin for their fruit-
ful discussions related to dopamine. We also thank Mathilde
Faideau, Ange ´lique Colin and Gilles Bonvento for helping
in setting up astrocyte cultures. Dr S. Rasika of Gap Junction
(www.gap-junction.com) assisted with English editing. We are
also grateful to Dr Sharon Schendel and Tara Mabry for
English editing. A.B. is the recipient of a post-doctoral fellow-
ship from the CEA. Y.T. is the recipient of a post-doctoral fel-
lowship from the Hereditary Disease Foundation. Funding to
pay the Open Access publication charges for this article was
provide by ... .
Conﬂict of Interest statement. None declared.
FUNDING
This work was supported by the CEA, CNRS and Hereditary
Disease Foundation. This study also beneﬁted from support
of the HighQ Foundation and NIH (NS 036821 for S.K.).
REFERENCES
1. Beal, M.F. (1992) Does impairment of energy metabolism result in
excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol.,
31, 119–130.
2. Harper, P.S. (1991) Huntington’s Disease. WB Saunders Company Ltd,
London.
3. Ferrante, R.J., Kowall, N.W., Beal, M.F., Martin, J.B., Bird, E.D. and
Richardson, E.P., Jr (1987) Morphologic and histochemical characteristics
of a spared subset of striatal neurons in Huntington’s disease.
J. Neuropathol. Exp. Neurol., 46, 12–27.
4. The Huntington Disease Collaborative Research Group (1993) A novel
gene containing a trinucleotide repeat that is expanded and unstable on
Huntington’s disease chromosomes. The Huntington’s Disease
Collaborative Research Group. Cell, 72, 971–983.
5. Graham, R.K., Deng, Y., Slow, E.J., Haigh, B., Bissada, N., Lu, G.,
Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z. et al. (2006) Cleavage
at the caspase-6 site is required for neuronal dysfunction and degeneration
due to mutant huntingtin. Cell, 125, 1179–1191.
6. Cattaneo, E., Zuccato, C. and Tartari, M. (2005) Normal huntingtin
function: an alternative approach to Huntington’s disease. Nat. Rev.
Neurosci., 6, 919–930.
7. Gervais, F.G., Singaraja, R., Xanthoudakis, S., Gutekunst, C.A., Leavitt,
B.R., Metzler, M., Hackam, A.S., Tam, J., Vaillancourt, J.P., Houtzager,
V. et al. (2002) Recruitment and activation of caspase-8 by the
Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat. Cell
Biol., 4, 95–105.
8. Rigamonti, D., Bauer, J.H., De-Fraja, C., Conti, L., Sipione, S., Sciorati,
C., Clementi, E., Hackam, A., Hayden, M.R., Li, Y. et al. (2000)
Wild-type huntingtin protects from apoptosis upstream of caspase-3.
J. Neurosci., 20, 3705–3713.
9. Rigamonti, D., Sipione, S., Goffredo, D., Zuccato, C., Fossale, E. and
Cattaneo, E. (2001) Huntingtin’s neuroprotective activity occurs via
inhibition of procaspase-9 processing. J. Biol. Chem., 276, 14545–14548.
10. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D.,
Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R.
et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in
Huntington’s disease. Science, 293, 493–498.
11. Gauthier, L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, J.P.,
Rangone, H., Cordelieres, F.P., De Mey, J., MacDonald, M.E., Lessmann,
V., Humbert, S. et al. (2004) Huntingtin controls neurotrophic support and
survival of neurons by enhancing BDNF vesicular transport along
microtubules. Cell, 118, 127–138.
12. Brouillet, E., Jacquard, C., Bizat, N. and Blum, D. (2005)
3-Nitropropionic acid: a mitochondrial toxin to uncover
physiopathological mechanisms underlying striatal degeneration in
Huntington’s disease. J. Neurochem., 95, 1521–1540.
13. Jakel, R.J. and Maragos, W.F. (2000) Neuronal cell death in Huntington’s
disease: a potential role for dopamine. Trends Neurosci., 23, 239–245.
14. Hoyt, K.R., Reynolds, I.J. and Hastings, T.G. (1997) Mechanisms of
dopamine-induced cell death in cultured rat forebrain neurons:
interactions with and differences from glutamate-induced cell death. Exp.
Neurol., 143, 269–281.
15. McLaughlin, B.A., Nelson, D., Erecinska, M. and Chesselet, M.F. (1998)
Toxicity of dopamine to striatal neurons in vitro and potentiation of cell
death by a mitochondrial inhibitor. J. Neurochem., 70, 2406–2415.
16. Cyr, M., Beaulieu, J.M., Laakso, A., Sotnikova, T.D., Yao, W.D., Bohn,
L.M., Gainetdinov, R.R. and Caron, M.G. (2003) Sustained elevation of
extracellular dopamine causes motor dysfunction and selective
degeneration of striatal GABAergic neurons. Proc. Natl Acad. Sci. USA,
100, 11035–11040.
17. Filloux, F. and Townsend, J.J. (1993) Pre- and postsynaptic neurotoxic
effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol.,
119, 79–88.
18. Reynolds, D.S., Carter, R.J. and Morton, A.J. (1998) Dopamine modulates
the susceptibility of striatal neurons to 3-nitropropionic acid in the rat
model of Huntington’s disease. J. Neurosci., 18, 10116–10127.
19. Bowyer, J.F., Clausing, P., Schmued, L., Davies, D.L., Binienda, Z.,
Newport, G.D., Scallet, A.C. and Slikker, W., Jr (1996) Parenterally
administered 3-nitropropionic acid and amphetamine can combine to
produce damage to terminals and cell bodies in the striatum. Brain Res.,
712, 221–229.
Human Molecular Genetics, 2008, Vol. 17, No. 10 145520. Charvin, D., Vanhoutte, P., Pages, C., Borrelli, E. and Caboche, J. (2005)
Unraveling a role for dopamine in Huntington’s disease: the dual role of
reactive oxygen species and D2 receptor stimulation. Proc. Natl Acad. Sci.
USA, 102, 12218–12223.
21. Cyr, M., Sotnikova, T.D., Gainetdinov, R.R. and Caron, M.G. (2006)
Dopamine enhances motor and neuropathological consequences of
polyglutamine expanded huntingtin. FASEB J., 20, 2541–2543.
22. Tang, T.S., Chen, X., Liu, J. and Bezprozvanny, I. (2007) Dopaminergic
signaling and striatal neurodegeneration in Huntington’s disease.
J. Neurosci., 27, 7899–7910.
23. Bae, B.I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y.,
Hayward, S.D., Moran, T.H., Montell, C., Ross, C.A. et al. (2005) p53
mediates cellular dysfunction and behavioral abnormalities in
Huntington’s disease. Neuron, 47, 29–41.
24. Sawa, A., Wiegand, G.W., Cooper, J., Margolis, R.L., Sharp, A.H.,
Lawler, J.F., Jr, Greenamyre, J.T., Snyder, S.H. and Ross, C.A. (1999)
Increased apoptosis of Huntington disease lymphoblasts associated with
repeat length-dependent mitochondrial depolarization. Nat. Med., 5,
1194–1198.
25. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R.,
Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial
calcium defects in Huntington’s disease are a direct effect of
polyglutamines. Nat. Neurosci., 5, 731–736.
26. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C.,
Muqit, M.M., Bird, E.D. and Beal, M.F. (1997) Oxidative damage and
metabolic dysfunction in Huntington’s disease: selective vulnerability of
the basal ganglia. Ann. Neurol., 41, 646–653.
27. Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, J.M. and
Schapira, A.H. (1996) Mitochondrial defect in Huntington’s disease
caudate nucleus. Ann. Neurol., 39, 385–389.
28. Benchoua, A., Trioulier, Y., Zala, D., Gaillard, M.C., Lefort, N., Dufour,
N., Saudou, F., Elalouf, J.M., Hirsch, E., Hantraye, P. et al. (2006)
Involvement of mitochondrial complex II defects in neuronal death
produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell,
17, 1652–1663.
29. Zala, D., Benchoua, A., Brouillet, E., Perrin, V., Gaillard, M.C., Zurn,
A.D., Aebischer, P. and Deglon, N. (2005) Progressive and selective
striatal degeneration in primary neuronal cultures using lentiviral vector
coding for a mutant huntingtin fragment. Neurobiol. Dis., 20, 785–798.
30. Jacquard, C., Trioulier, Y., Cosker, F., Escartin, C., Bizat, N., Hantraye,
P., Cancela, J.M., Bonvento, G. and Brouillet, E. (2006) Brain
mitochondrial defects amplify intracellular [Ca2þ] rise and
neurodegeneration but not Ca2þ entry during NMDA receptor activation.
FASEB J., 20, 1021–1023.
31. Arango, M., Holbert, S., Zala, D., Brouillet, E., Pearson, J., Regulier, E.,
Thakur, A.K., Aebischer, P., Wetzel, R., Deglon, N. et al. (2006) CA150
expression delays striatal cell death in overexpression and knock-in
conditions for mutant huntingtin neurotoxicity. J. Neurosci., 26, 4649–
4659.
32. Missale, C., Nash, S.R., Robinson, S.W., Jaber, M. and Caron, M.G.
(1998) Dopamine receptors: from structure to function. Physiol. Rev., 78,
189–225.
33. Beaulieu, J.M., Sotnikova, T.D., Marion, S., Lefkowitz, R.J., Gainetdinov,
R.R. and Caron, M.G. (2005) An Akt/beta-arrestin 2/PP2A signaling
complex mediates dopaminergic neurotransmission and behavior. Cell,
122, 261–273.
34. Brami-Cherrier, K., Valjent, E., Garcia, M., Pages, C., Hipskind, R.A. and
Caboche, J. (2002) Dopamine induces a PI3-kinase-independent
activation of Akt in striatal neurons: a new route to cAMP response
element-binding protein phosphorylation. J. Neurosci., 22, 8911–8921.
35. Kroemer, G. and Reed, J.C. (2000) Mitochondrial control of cell death.
Nat. Med., 6, 513–519.
36. Toescu, E.C., Verkhratsky, A. and Landﬁeld, P.W. (2004) Ca2þ
regulation and gene expression in normal brain aging. Trends Neurosci.,
27, 614–620.
37. Werner, E. and Werb, Z. (2002) Integrins engage mitochondrial function
for signal transduction by a mechanism dependent on Rho GTPases.
J. Cell. Biol., 158, 357–368.
38. Brouillet, E., Conde, F., Beal, M.F. and Hantraye, P. (1999) Replicating
Huntington’s disease phenotype in experimental animals. Prog.
Neurobiol., 59, 427–468.
39. Antonini, A., Leenders, K.L., Spiegel, R., Meier, D., Vontobel, P.,
Weigell-Weber, M., Sanchez-Pernaute, R., de Yebenez, J.G., Boesiger, P.,
Weindl, A. et al. (1996) Striatal glucose metabolism and dopamine D2
receptor binding in asymptomatic gene carriers and patients with
Huntington’s disease. Brain, 119, 2085–2095.
40. Bibb, J.A., Yan, Z., Svenningsson, P., Snyder, G.L., Pieribone, V.A.,
Horiuchi, A., Nairn, A.C., Messer, A. and Greengard, P. (2000) Severe
deﬁciencies in dopamine signaling in presymptomatic Huntington’s
disease mice. Proc. Natl Acad. Sci. USA, 97, 6809–6814.
41. Charvin, D., Roze, E., Perrin, V., Deyts, C., Betuing, S., Page `s, C.,
Re ´gulier, E., Luthi-Carter, R., Brouillet, E., Deglon, E. et al. (2007)
Haloperidol protects striatal neurons from dysfunction induced by mutated
huntingtin in vivo. Neurobiol. Dis., in press.
42. Stack, E.C., Dedeoglu, A., Smith, K.M., Cormier, K., Kubilus, J.K.,
Bogdanov, M., Matson, W.R., Yang, L., Jenkins, B.G., Luthi-Carter, R. et
al. (2007) Neuroprotective effects of synaptic modulation in Huntington’s
disease R6/2 mice. J. Neurosci., 27, 12908–12915.
43. Vega, C., Pellerin, L., Dantzer, R. and Magistretti, P.J. (2002) Long-term
modulation of glucose utilization by IL-1 alpha and TNF-alpha in
astrocytes: Naþ pump activity as a potential target via distinct signaling
mechanisms. Glia, 39, 10–18.
44. Hottinger, A.F., Azzouz, M., Deglon, N., Aebischer, P. and Zurn, A.D.
(2000) Complete and long-term rescue of lesioned adult motoneurons by
lentiviral-mediated expression of glial cell line-derived neurotrophic
factor in the facial nucleus. J. Neurosci., 20, 5587–5593.
45. Galas, M.C., Bizat, N., Cuvelier, L., Bantubungi, K., Brouillet, E.,
Schiffmann, S.N. and Blum, D. (2004) Death of cortical and striatal
neurons induced by mitochondrial defect involves differential molecular
mechanisms. Neurobiol. Dis., 15, 152–159.
46. Munujos, P., Coll-Canti, J., Gonzalez-Sastre, F. and Gella, F.J. (1993)
Assay of succinate dehydrogenase activity by a colorimetric-continuous
method using iodonitrotetrazolium chloride as electron acceptor. Anal.
Biochem., 212, 506–509.
1456 Human Molecular Genetics, 2008, Vol. 17, No. 10